GSK plc Files 6-K on Share Transaction
Ticker: GSK · Form: 6-K · Filed: 2026-04-07T08:22:11-04:00
Sentiment: neutral
Topics: share-transaction, corporate-action, 6-K
TL;DR
GSK bought back its own shares, filing details out today.
AI Summary
GSK plc filed a Form 6-K on April 7, 2026, reporting a transaction in its own shares. The filing details a transaction involving GSK plc's own shares, with the company's registered address at 79 New Oxford Street, London, WC1A 1DG, United Kingdom.
Why It Matters
This filing indicates GSK plc is actively managing its share capital, which could signal buybacks or other corporate actions affecting share count and potentially value.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a share transaction by the company itself, with no immediate indication of significant financial distress or major strategic shifts.
Key Players & Entities
- GSK plc (company) — Filer of the 6-K report
- 0001131399 (company) — CIK number for GSK plc
- 79 NEW OXFORD STREET LONDON United Kingdom WC1A 1DG (company) — Mailing and Business Address for GSK plc
- April 7, 2026 (date) — Filing Date and Period of Report
FAQ
What specific type of transaction in its own shares did GSK plc report?
The filing is titled 'TRANSACTION IN OWN SHARES' but does not specify the exact nature (e.g., buyback, issuance) within the provided text.
When was this Form 6-K filed and for what reporting period?
The Form 6-K was filed on April 7, 2026, and the period of report is also April 7, 2026.
What is GSK plc's registered address as per this filing?
GSK plc's mailing and business address is 79 New Oxford Street, London, United Kingdom, WC1A 1DG.
What is the CIK number associated with GSK plc in this filing?
The CIK number for GSK plc is 0001131399.
What is the SIC code listed for GSK plc?
The SIC code listed is 2834 for Pharmaceutical Preparations.
Filing Stats: 3,068 words · 12 min read · ~10 pages · Grade level 2.8 · Accepted 2026-04-07 08:22:11
Filing Documents
- a3393z.htm (6-K) — 3779KB
- 0001654954-26-003274.txt ( ) — 3780KB
From the Filing
IN OWN SHARES a3393z   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of April 2026   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .   Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase:   02 April 2026   Aggregate number of ordinary shares of  31¼  pence each purchased:   335,000   Lowest price paid per share (GBp):   2,093.00p   Highest price paid per share (GBp):   2,161.00p   Volume-weighted average price paid per share (GBp):   2,121.37p     The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 17 February 2026. Since 17 February 2026, the Company has purchased 16,901,521 ordinary shares.   Following the above purchase, the Company will hold 256,792,615 ordinary shares in treasury and have 4,059,387,166 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,059,387,166. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 6.33 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases Shares purchased:    GSK plc (ISIN: GB00BN7SWP63) Date of purchases:      02 April 2026 Investment firm:         BNP Paribas SA   Aggregated information per trading venue: Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   32,837   2,161.00p   2,103.00p   2,117.98p   CHIX   64,965   2,161.00p   2,093.00p   2,120.06p   XLON   237,198   2,161.00p   2,093.00p   2,122.19p     Individual transactions: Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   64   2097.0   XLON   02-Apr-2026   08:00:13   20260402183959308   128   2097.0   XLON   02-Apr-2026   08:00:13   20260402183959310   225   2094.0   XLON   02-Apr-2026   08:00:15   20260402183959520   91   2094.0   CHIX   02-Apr-2026